For the quarter ending 2025-09-30, BCLI has $1,380K in assets. $9,073K in debts. $5K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 5 | 824 | ||
| Other accounts receivable | 80 | 106 | ||
| Prepaid expenses and other current assets | 423 | 585 | ||
| Total current assets | 508 | 1,515 | ||
| Prepaid expenses and other long-term assets | 24 | 24 | ||
| Restricted cash | 231 | 201 | ||
| Operating lease right of use asset (note 3) | 334 | 495 | ||
| Property and equipment, net | 283 | 331 | ||
| Total long-term assets | 872 | 1,051 | ||
| Total assets | 1,380 | 2,566 | ||
| Accounts payables | 6,420 | 5,997 | ||
| Accrued expenses | 350 | 367 | ||
| Short-term loans (note 7) | 101 | 101 | ||
| Operating lease liability (note 3) | 276 | 381 | ||
| Employees related liability | 1,876 | 1,682 | ||
| Warrants liability (note 4) | - | 0 | ||
| Total current liabilities | 9,023 | 8,528 | ||
| Operating lease liability (note 3) | 50 | 95 | ||
| Total long-term liabilities | 50 | 95 | ||
| Total liabilities | 9,073 | 8,623 | ||
| Common stock of 0.00005 par value - authorized 250,000,000 shares at september 30, 2025 and at december 31, 2024 respectively issued and outstanding 11,034,775 and 6,141,762 shares at september 30, 2025 and december 31, 2024 respectively | 16 | - | ||
| Additional paid-in-capital | 226,916 | 226,446 | ||
| Treasury stocks | 116 | 116 | ||
| Accumulated deficit | -234,509 | - | ||
| Total stockholders' deficit | -7,693 | -6,057 | ||
| Total liabilities and stockholders' deficit | 1,380 | 2,566 | ||
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)